logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Obsessivecompulsive Disorder

    FiltersReset Filters
    30 results

    • clomipramine hydrochloride

      (Clomipramine Hydrochloride)
      Leading Pharma, LLC
      Usage: Clomipramine Hydrochloride capsules are indicated for treating obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD) that cause marked distress or significantly interfere with functioning. Effectiveness is supported by clinical studies showing substantial improvement in OCD symptoms among treated patients. Long-term efficacy has not been systematically evaluated.

    • clomipramine hydrochloride

      (Clomipramine Hydrochloride)
      Rising Pharma Holdings, Inc.
      Usage: Clomipramine hydrochloride capsules are indicated for treating obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD) that cause significant distress or interfere with functioning. Its effectiveness was demonstrated in clinical studies involving adults and children with moderate-to-severe OCD. Long-term use requires reevaluation by a physician.

    • clomipramine hydrochloride

      (Clomipramine Hydrochloride)
      VGYAAN Pharmaceuticals LLC
      Usage: Clomipramine hydrochloride capsules are indicated for treating obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). Effective in moderate to severe cases, it helps reduce symptoms that cause significant distress or impairment in social and occupational functioning. Long-term effectiveness has not been systematically evaluated.

    • clomipramine hydrochloride

      (CLOMIPRAMINE HYDROCHLORIDE)
      Alembic Pharmaceuticals Limited
      Usage: Clomipramine hydrochloride capsules are indicated for treating obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD) that cause significant distress or dysfunction. Its efficacy has been demonstrated in studies with both adults and adolescents showing marked symptom reduction. Long-term use effectiveness requires periodic reevaluation.

    • fluoxetine

      (Fluoxetine Hydrochloride)
      ScieGen Pharmaceuticals, Inc.
      Usage: Fluoxetine is indicated for the treatment of Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, and Panic Disorder. In combination with Olanzapine, it is used for depressive episodes in Bipolar I Disorder and treatment-resistant depression. Monotherapy with fluoxetine is not suitable for these latter conditions.

    • fluoxetine

      (Fluoxetine Hydrochloride)
      TIME CAP LABORATORIES, INC.
      Usage: Fluoxetine capsules are indicated for the treatment of Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, and Panic Disorder. In combination with Olanzapine, it treats depressive episodes in Bipolar I Disorder and treatment-resistant depression. Monitoring and careful consideration are advised in these clinical applications.

    • fluoxetine

      (Fluoxetine Hydrochloride)
      Vensun Pharmaceuticals, Inc.
      Usage: Fluoxetine is indicated for the treatment of Major Depressive Disorder, Obsessive Compulsive Disorder (OCD), Bulimia Nervosa, and Panic Disorder. In combination with olanzapine, it treats depressive episodes associated with Bipolar I Disorder. Monotherapy with fluoxetine is not recommended for Bipolar I Disorder.

    • fluoxetine

      (Fluoxetine Hydrochloride)
      Aurobindo Pharma Limited
      Usage: Fluoxetine capsules are indicated for the acute and maintenance treatment of Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, and Panic Disorder. Additionally, in combination with Olanzapine, they treat depressive episodes in Bipolar I Disorder and treatment-resistant depression.

    • fluoxetine

      (fluoxetine)
      Strides Pharma Science Limited
      Usage: Fluoxetine is indicated for the acute and maintenance treatment of Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, and Panic Disorder in adults and select pediatric patients. Long-term effectiveness should be periodically re-evaluated by physicians for each individual patient.

    • fluoxetine

      (Fluoxetine)
      Cadila Pharmaceuticals Limited
      Usage: Fluoxetine capsules are indicated for treating Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, and Panic Disorder. They can be combined with Olanzapine for Bipolar I Disorder and Treatment Resistant Depression. Monotherapy is not approved for Bipolar I or treatment-resistant cases.